Mutant INS-gene induced diabetes of youth: proinsulin cysteine residues impose dominant-negative inhibition on wild-type proinsulin transport
- PMID: 20948967
- PMCID: PMC2952628
- DOI: 10.1371/journal.pone.0013333
Mutant INS-gene induced diabetes of youth: proinsulin cysteine residues impose dominant-negative inhibition on wild-type proinsulin transport
Erratum in
- PLoS One. 2010;5(10) doi: 10.1371/annotation/6d5e12f2-defc-48b5-84f6-43253f593a2a
Abstract
Recently, a syndrome of Mutant INS-gene-induced Diabetes of Youth (MIDY, derived from one of 26 distinct mutations) has been identified as a cause of insulin-deficient diabetes, resulting from expression of a misfolded mutant proinsulin protein in the endoplasmic reticulum (ER) of insulin-producing pancreatic beta cells. Genetic deletion of one, two, or even three alleles encoding insulin in mice does not necessarily lead to diabetes. Yet MIDY patients are INS-gene heterozygotes; inheritance of even one MIDY allele, causes diabetes. Although a favored explanation for the onset of diabetes is that insurmountable ER stress and ER stress response from the mutant proinsulin causes a net loss of beta cells, in this report we present three surprising and interlinked discoveries. First, in the presence of MIDY mutants, an increased fraction of wild-type proinsulin becomes recruited into nonnative disulfide-linked protein complexes. Second, regardless of whether MIDY mutations result in the loss, or creation, of an extra unpaired cysteine within proinsulin, Cys residues in the mutant protein are nevertheless essential in causing intracellular entrapment of co-expressed wild-type proinsulin, blocking insulin production. Third, while each of the MIDY mutants induces ER stress and ER stress response; ER stress and ER stress response alone appear insufficient to account for blockade of wild-type proinsulin. While there is general agreement that ultimately, as diabetes progresses, a significant loss of beta cell mass occurs, the early events described herein precede cell death and loss of beta cell mass. We conclude that the molecular pathogenesis of MIDY is initiated by perturbation of the disulfide-coupled folding pathway of wild-type proinsulin.
Conflict of interest statement
Figures
Similar articles
-
Distinct states of proinsulin misfolding in MIDY.Cell Mol Life Sci. 2021 Aug;78(16):6017-6031. doi: 10.1007/s00018-021-03871-1. Epub 2021 Jul 10. Cell Mol Life Sci. 2021. PMID: 34245311 Free PMC article.
-
Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes.Ann N Y Acad Sci. 2018 Apr;1418(1):5-19. doi: 10.1111/nyas.13531. Epub 2018 Jan 28. Ann N Y Acad Sci. 2018. PMID: 29377149 Free PMC article. Review.
-
Disulfide Mispairing During Proinsulin Folding in the Endoplasmic Reticulum.Diabetes. 2016 Apr;65(4):1050-60. doi: 10.2337/db15-1345. Epub 2016 Jan 28. Diabetes. 2016. PMID: 26822090 Free PMC article.
-
Endoplasmic reticulum oxidoreductin-1α (Ero1α) improves folding and secretion of mutant proinsulin and limits mutant proinsulin-induced endoplasmic reticulum stress.J Biol Chem. 2013 Oct 25;288(43):31010-8. doi: 10.1074/jbc.M113.510065. Epub 2013 Sep 10. J Biol Chem. 2013. PMID: 24022479 Free PMC article.
-
Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.Trends Endocrinol Metab. 2010 Nov;21(11):652-9. doi: 10.1016/j.tem.2010.07.001. Epub 2010 Aug 18. Trends Endocrinol Metab. 2010. PMID: 20724178 Free PMC article. Review.
Cited by
-
A Review of the Biosynthesis and Structural Implications of Insulin Gene Mutations Linked to Human Disease.Cells. 2023 Mar 25;12(7):1008. doi: 10.3390/cells12071008. Cells. 2023. PMID: 37048081 Free PMC article. Review.
-
IER3IP1 is critical for maintaining glucose homeostasis through regulating the endoplasmic reticulum function and survival of β cells.Proc Natl Acad Sci U S A. 2022 Nov 8;119(45):e2204443119. doi: 10.1073/pnas.2204443119. Epub 2022 Nov 2. Proc Natl Acad Sci U S A. 2022. PMID: 36322741 Free PMC article.
-
Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in β-Cells.Biomedicines. 2022 Mar 30;10(4):814. doi: 10.3390/biomedicines10040814. Biomedicines. 2022. PMID: 35453564 Free PMC article.
-
Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation.Front Endocrinol (Lausanne). 2022 Mar 1;13:821069. doi: 10.3389/fendo.2022.821069. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35299972 Free PMC article.
-
Peptide Model of the Mutant Proinsulin Syndrome. II. Nascent Structure and Biological Implications.Front Endocrinol (Lausanne). 2022 Mar 1;13:821091. doi: 10.3389/fendo.2022.821091. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35299958 Free PMC article.
References
-
- Vinik A, Bell G. Mutant insulin syndromes. Horm Metab Res. 1988;20:1–10. - PubMed
-
- Barbetti F, Raben N, Kadowaki T, Cama A, Accili D, et al. Two unrelated patients with familial hyperproinsulinemia due to a mutation substituting histidine for arginine at position 65 in the proinsulin molecule: identification of the mutation by direct sequencing of genomic deoxyribonucleic acid amplified by polymerase chain reaction. J Clin Endocrinol Metab. 1990;71:164–169. - PubMed
-
- Steiner DF, Tager HS, Chan SJ, Nanjo K, Sanke T, et al. Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care. 1990;13:600–609. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases